{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Thomas KR"],"funding":["NIA NIH HHS","CSRD VA"],"pagination":["e12238"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8515224"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["<h4>Introduction</h4>Objectively-defined subtle cognitive decline (Obj-SCD) and plasma phosphorylated-tau181 (p-tau181) are promising early Alzheimer's disease (AD) markers. However, associations between Obj-SCD and p-tau181, and their combined prognostic potential, are unknown.<h4>Methods</h4>Baseline and 4-year longitudinal p-tau181 changes were compared across cognitively unimpaired (CU; <i>n</i> = 402), Obj-SCD (<i>n</i> = 199), and mild cognitive impairment (MCI; <i>n</i> = 346) groups. CU and Obj-SCD participants were further classified as p-tau181-positive or negative.<h4>Results</h4>CU and Obj-SCD has lower baseline p-tau181 than MCI and did not differ from one another. Longitudinally, Obj-SCD had the steepest p-tau181 increase. Obj-SCD/p-tau181-positive participants had the fastest rates of amyloid accumulation, cognitive decline, and functional decline.<h4>Conclusions</h4>Despite assumptions that cognitive changes invariably follow biomarker changes, early neuropsychological difficulties may emerge before/concurrently with plasma p-tau181 changes. Combining Obj-SCD and p-tau181, two potentially accessible early markers, was associated with the faster declines in AD-related outcomes."],"journal":["Alzheimer's & dementia (Amsterdam, Netherlands)"],"pubmed_title":["Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease-related declines."],"pmcid":["PMC8515224"],"funding_grant_id":["R01 AG063782","IK2 CX001415","R03 AG070435","I01 CX001842","IK2 CX001865","R01 AG049810","P30 AG062429","R01 AG054049"],"pubmed_authors":["Alzheimer's Disease Neuroimaging Initiative","Bondi MW","Bangen KJ","Edmonds EC","Weigand AJ","Walker KS","Thomas KR","Galasko DR"],"additional_accession":[]},"is_claimable":false,"name":"Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease-related declines.","description":"<h4>Introduction</h4>Objectively-defined subtle cognitive decline (Obj-SCD) and plasma phosphorylated-tau181 (p-tau181) are promising early Alzheimer's disease (AD) markers. However, associations between Obj-SCD and p-tau181, and their combined prognostic potential, are unknown.<h4>Methods</h4>Baseline and 4-year longitudinal p-tau181 changes were compared across cognitively unimpaired (CU; <i>n</i> = 402), Obj-SCD (<i>n</i> = 199), and mild cognitive impairment (MCI; <i>n</i> = 346) groups. CU and Obj-SCD participants were further classified as p-tau181-positive or negative.<h4>Results</h4>CU and Obj-SCD has lower baseline p-tau181 than MCI and did not differ from one another. Longitudinally, Obj-SCD had the steepest p-tau181 increase. Obj-SCD/p-tau181-positive participants had the fastest rates of amyloid accumulation, cognitive decline, and functional decline.<h4>Conclusions</h4>Despite assumptions that cognitive changes invariably follow biomarker changes, early neuropsychological difficulties may emerge before/concurrently with plasma p-tau181 changes. Combining Obj-SCD and p-tau181, two potentially accessible early markers, was associated with the faster declines in AD-related outcomes.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-06-12T10:26:14.209Z","creation":"2025-04-06T10:19:48.567Z"},"accession":"S-EPMC8515224","cross_references":{"pubmed":["34692978"],"doi":["10.1002/dad2.12238"]}}